Clinical Trials Logo

Advanced Endometrial Cancer clinical trials

View clinical trials related to Advanced Endometrial Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05106127 Not yet recruiting - Clinical trials for Advanced Endometrial Cancer

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Start date: March 2025
Phase: Phase 2
Study type: Interventional

This is a Phase 2 trial Safety Lead-in trial conducted in 3 cohorts of patients. A safety lead-in study of the impact of adding the Repurposed Drugs a third agent will be conducted prior to opening enrollment into the compassionate use study. All patients enrolled in the safety lead-in study may continue long-term treatment under this protocol without interruption of dosing.

NCT ID: NCT05077215 Not yet recruiting - Clinical trials for Advanced Endometrial Cancer

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Start date: December 2024
Phase: Phase 3
Study type: Interventional

This is a Phase 3, multicenter, randomized, open-label trial to evaluate whether EG-007 plus Len+Pem is superior to Len+Pem alone in patients with advanced endometrial cancer (Stage III or IV). This trial will be preceded by a safety lead-in study with up to 28 patients (the safety lead-in is a separate, free-standing protocol). Approximately 450 patients will be randomized equally (1:1) to receive EG-007 plus Len+Pem or Len+Pem alone. The randomization will be stratified by the following stratification factors: - Diagnosis Classification (advanced Stage III/IV vs. recurrent endometrial cancer) - ECOG score at baseline (0 vs 1) - Geographic region (Asia vs ROW)